Boardroom Alpha
Boardroom Alpha
HNVR · Current Report (Form 8-K) · Filed June 1, 2026

Hanover Bancorp Inc — Current Report (Form 8-K)

Form
8-K
Filed
June 1, 2026
Period
May 28, 2026
Ticker
HNVR
Accession
0001104659-26-068886
Boardroom Alpha · Filing insights

Shareholders approved the 2026 Equity Incentive Plan and elected three directors for three-year terms. They also ratified Crowe LLP as the independent auditor.

About Hanover Bancorp Inc
Market cap
$190M
1Y TSR
+26.6%
3Y TSR
+15.7%
Board grade
B
Sector
Financial Services
CEO
Michael P Puorro
Last annual meeting: May 28, 2026 · View full Hanover Bancorp Inc profile →
Hanover Bancorp, Inc. /MD_May 28, 2026

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT TO

SECTION 13 OR 15(d) OF THE SECURITIES

EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): May 28, 2026

HANOVER BANCORP, INC.

(Exact name of registrant as specified in its charter)

Maryland

001-41384

81-3324480

(State or other jurisdiction of incorporation)

(Commission File Number)

(IRS Employer Identification No.)

80 East Jericho Turnpike, Mineola, New York

11501

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: (516) 548-8500

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading symbol

Name of each exchange on which registered

Common stock

HNVR

NASDAQ

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On May 28, 2026, the shareholders of Hanover Bancorp, Inc. (the “Company”) approved the Hanover Bancorp, Inc. 2026 Equity Incentive Plan (the “Plan”).  The material terms of the Plan are summarized on pages 25 through 31 of the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 23, 2026 (the “Proxy Statement”), which description is incorporated herein by reference.  

The foregoing description of the Plan does not purport to be complete and is qualified in its entirety by reference to the full text of the Plan, a copy of which was included as Appendix A to the Proxy Statement.

Item 5.07Submission of Matters to a Vote of Security Holders.

The annual meeting of the shareholders of the Company was held on May 28, 2026.  The final results for each of the matters submitted to a vote of shareholders at the annual meeting are as follows:

1.

The following individuals were elected as directors, each for a three-year term, by the following vote:

FOR

WITHHELD

Michael Katz

4,651,759

174,675

John R. Sorrenti

4,769,855

56,579

Philip Okun

4,642,366

184,068

There were 903,723 broker non-votes on the proposal.

2.

The Hanover Bancorp, Inc. 2026 Equity Incentive Plan was approved by the shareholders by the following vote:

FOR

AGAINST

ABSTAIN

4,755,228

27,522

43,684

There were 903,723 broker non-votes on the proposal.

3.

The appointment of Crowe LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified by the shareholders by the following vote:

FOR

AGAINST

ABSTAIN

5,725,927

2,908

1,322

There were no broker non-votes on the proposal.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

HANOVER BANCORP, INC.

Date: June 1, 2026

By:

/s/ Lance P. Burke

Lance P. Burke

Senior Executive Vice President and

Chief Financial Officer

From this filing to the file

Every SEC filing, parsed structured.

Boardroom Alpha indexes every 8-K, 10-K, 10-Q, and proxy back to 2000 — vote tabulations, comp tables, red flags, insider transactions, all queryable the day they hit EDGAR.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Hanover Bancorp Inc (HNVR)

Reference

Frequently asked questions

When did Hanover Bancorp Inc file this 8-K?
Hanover Bancorp Inc (HNVR) filed this Current Report (Form 8-K) with the SEC on June 1, 2026. The accession number assigned by EDGAR is 0001104659-26-068886.
What does an 8-K disclose?
Form 8-K is the SEC's current-report form, used to disclose material events between periodic reports (10-K / 10-Q). Triggers include CEO/CFO departures, acquisitions, bankruptcies, earnings releases, auditor changes, changes in fiscal year, and amendments to corporate governance. Each 8-K is keyed to one or more Item numbers (1.01 through 9.01).
What is the key takeaway from this filing?
Shareholders approved the 2026 Equity Incentive Plan and elected three directors for three-year terms. They also ratified Crowe LLP as the independent auditor. This is Boardroom Alpha's one-line summary of the current report; see the full filing text above for the formal disclosure.
What Item codes does an 8-K cover?
An 8-K's Item codes (1.01 through 9.01) specify what kind of event is being disclosed — e.g. Item 1.01 for entering a material agreement, Item 5.02 for departure/election of directors and executive officers, Item 8.01 for other events. The Item codes for this 8-K appear in the filing text above.
Where can I find Hanover Bancorp Inc's prior current reports on EDGAR?
The SEC EDGAR browser lists every 8-K Hanover Bancorp Inc has filed under CIK 1828588, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer